What Wave Life Sciences does

Wave Life Sciences is a clinical-stage biotechnology company developing RNA-based therapeutics for serious genetic and metabolic diseases, using its proprietary PRISM (Platform for RNA-based Integrated Sciences and Medicines) platform. The platform combines multiple RNA-targeting modalities — RNA editing (AIMers), splicing, RNA interference (siRNA), and antisense silencing — alongside stereochemistry-controlled chemistry innovations including stereopure oligonucleotides, PN (phosphoryl guanidine) backbone chemistry, and the N3U base modification. Wave's clinical pipeline addresses Alpha-1 antitrypsin deficiency (WVE-006, the first RNA editing program in clinical trials), Duchenne muscular dystrophy (WVE-N531), Huntington's disease (WVE-003), and obesity (WVE-007, an INHBE-targeting GalNAc-siRNA). The company serves patients with high unmet medical needs and supports its work through in-house cGMP manufacturing at a 90,000 sq ft Lexington, MA facility.

Wave generates revenue through strategic collaboration and milestone-based partnerships with pharmaceutical companies rather than product sales, as no compounds are yet approved or commercialized. The dominant commercial relationship is a 2022 collaboration with GSK ($170M upfront, up to $2.8B in potential milestones), under which WVE-006 was returned to Wave in February 2026 and a fourth program has been selected. A prior Takeda collaboration was terminated in October 2024. Wave has raised approximately $720M in public equity offerings since 2022, holds $544.6M in cash at end of Q1 2026 (runway into Q3 2028), maintains a market capitalization of approximately $1.4B, and is redomiciling its Singapore parent to Delaware, USA. The go-to-market strategy emphasizes scientific and investor communications through healthcare conferences, medical congresses, patient advocacy partnerships (Alpha-1 Foundation, MDA, HDSA), and standard pharmaceutical distribution channels upon future regulatory approval.

Name

Wave Life Sciences

Legal name

Wave Life Sciences Ltd.

Website

https://wavelifesciences.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Wave Life Sciences is a clinical-stage RNA medicines company developing first-in-class RNA editing, splicing, and RNAi therapeutics for serious genetic diseases and obesity, using its proprietary stereochemistry-controlled PRISM platform and in-house cGMP manufacturing.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• RNA therapeutics
• Oligonucleotide drug development
• Rare disease medicines
• RNA editing therapy
• Antisense oligonucleotide therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Collaboration and Partnership Revenue: Wave Life Sciences generates revenue through strategic collaborations with pharmaceutical companies. In 2022, Wave received $170 million upfront payment from GSK for a strategic collaboration to develop oligonucleotide therapeutics. The collaboration includes potential milestone payments up to $2.8 billion across multiple programs. Revenue recognition includes upfront payments, milestone payments upon achievement of development and regulatory milestones, and potential royalty payments on future product sales.
2. Future Product Sales: Pre-revenue clinical stage company. No products currently approved or commercialized. The company is advancing multiple clinical programs through development toward potential regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Wave Life Sciences is a clinical-stage biotechnology company that designs and develops RNA-targeted therapeutics using its proprietary PRISM® platform. The company builds stereopure oligonucleotide drug candidates across four modalities—RNA editing (AIMers), RNA interference (siRNA), splicing, and antisense silencing—addressing rare genetic diseases such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, as well as prevalent conditions such as obesity. Pipeline assets are advanced through clinical trials and supported by in-house cGMP manufacturing, with revenue generated today primarily through strategic collaborations with large pharmaceutical partners.

Product overview

Wave Life Sciences is a clinical-stage RNA medicines company advancing a diversified pipeline of first- or best-in-class therapeutics using its proprietary PRISM® platform. The company develops multiple RNA-targeting modalities including RNA editing (AIMers), splicing, RNA interference (RNAi), and antisense silencing. The clinical pipeline includes WVE-007 (INHBE GalNAc-siRNA for obesity in Phase 2a), WVE-006 (RNA editing for AATD in Phase 1b/2a), WVE-N531 (splicing for DMD in Phase 2), and WVE-003 (allele-selective silencing for Huntington's disease in Phase 1/2). Preclinical programs include WVE-008 for liver disease. The company operates in-house GMP manufacturing capabilities at its Lexington, Massachusetts facility.

Differentiator

Problem solved

Functional benefit

Brands

• PRISM® Platform: Wave's proprietary RNA medicines platform that combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs treating both rare and prevalent disorders.

Products and services

• WVE-007 (INHBE GalNAc-siRNA) Investigational GalNAc-conjugated siRNA targeting the INHBE gene for obesity and cardiometabolic diseases; uses RNA interference to silence INHBE. Demonstrated 14% placebo-adjusted visceral fat reduction and 2.4% lean mass increase at six months after a single 240 mg dose in Phase 1.
• WVE-006 (GalNAc-RNA Editing / AIMer) Investigational GalNAc-conjugated AIMer RNA editing oligonucleotide targeting the SERPINA1 gene for alpha-1 antitrypsin deficiency (AATD). Industry's first RNA editing compound to enter the clinic.
• WVE-N531 Stereopure antisense oligonucleotide designed to skip exon 53 for Duchenne muscular dystrophy (DMD), restoring the mRNA reading frame to enable functional dystrophin protein production.
• WVE-003 Antisense oligonucleotide designed to selectively target SNP3 associated with mutant huntingtin (mHTT) mRNA while preserving wild-type HTT protein in Huntington's disease.
• WVE-008 (PNPLA3 GalNAc) Preclinical RNA editing oligonucleotide program targeting PNPLA3 for liver disease, with potential applicability to approximately 9 million patients in the U.S. and Europe.
• PRISM® Platform Proprietary RNA medicines discovery and development platform combining multiple modalities (RNA editing, splicing, RNA interference, antisense silencing) with stereochemistry-controlled chemistry innovations (PN chemistry, N3U, GalNAc) and human genetics insights. Foundation for Wave's internal pipeline and partnership pipeline.

Quantifiable outcome

• WVE-007 (obesity): 14% placebo-adjusted visceral fat reduction at six months following single 240mg dose; 5% total fat reduction; 2.4% lean mass increase; 88% suppression of serum Activin E sustained for seven months
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered minor, flagship and core.

• Alpha-1 Foundation (AlphaDetect)minorStrategic or Co-development Partner · 19 May 2026Wave Life Sciences became an inaugural industry sponsor of AlphaDetect, a nonprofit organization founded by the Alpha-1 Foundation, to accelerate detection of Alpha-1 Antitrypsin Deficiency. AlphaDetect provides free genetic testing and expands detection strategies and provider education efforts. The sponsorship aligns with Wave's existing Alpha-1 pipeline program (WVE-006).
• GlaxoSmithKline (GSK)flagshipStrategic or Co-development Partner · 13 December 2022Wave Life Sciences and GSK announced a strategic collaboration to develop oligonucleotide therapeutics, including Wave's RNA editing program WVE-006. The partnership combines Wave's PRISM platform and GSK's genetic insights to advance multiple preclinical programs targeting genetic diseases. Wave received $170 million upfront payment with potential milestone payments up to $2.8 billion. In February 2026, GSK returned rights to WVE-006 to Wave, but the broader collaboration remains active with GSK having selected a fourth program under the agreement.
• Takeda PharmaceuticalcoreStrategic or Co-development Partner · 13 December 2022Wave had an active collaboration with Takeda, which was terminated in October 2024. The collaboration previously supported development activities but is no longer active.
• AsuragenminorStrategic or Co-development PartnerWave has a collaboration with Asuragen extending the reach of the PRISM discovery and drug development platform into therapeutic areas where Wave may offer competitive advantage.
• ExpressionEditsminorStrategic or Co-development PartnerPaul Bolno, CEO of Wave Life Sciences, serves as Chairman of the Board of Directors to ExpressionEdits, indicating a strategic relationship.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Alnylam Pharmaceuticals: Leading RNAi therapeutics company with approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) using GalNAc-conjugated siRNAs. Direct competitor to Wave's WVE-007 INHBE program in liver-targeted RNA interference, and both companies pursue rare disease indications through oligonucleotide platforms with in-house manufacturing.
• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide therapeutics with multiple approved products (Spinraza, Tegsedi, Waylivra) and a deep clinical pipeline including programs in Huntington's disease (tominersen competitor to WVE-003) and DMD. Ionis shares Wave's modality focus on stereochemistry-controlled oligonucleotides targeting serious genetic diseases.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company developing GalNAc-conjugated siRNAs targeting liver and extrahepatic tissues. Overlaps with Wave's GalNAc-siRNA WVE-007 in cardiometabolic diseases and shares the TRiM and other delivery platforms, making it a direct competitor in the oligonucleotide space.
• ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer platform leveraging ADAR-mediated A-to-I editing, directly comparable to Wave's AIMer technology. Both companies pursue RNA editing as a new therapeutic modality, though ProQR has focused on genetic diseases including AATD, similar to Wave's WVE-006.
• Sarepta Therapeutics: Commercial-stage DMD company with approved exon-skipping ASOs (Exondys 51, Vyondys 53, Amondys 45). Wave's WVE-N531 (exon 53 skipping) directly competes in the same Duchenne muscular dystrophy patient population, making Sarepta the most established commercial competitor for Wave's DMD program.
• Stoke Therapeutics: Clinical-stage antisense oligonucleotide company developing TANGO platform for RNA-based treatments of severe genetic diseases, with lead program in Dravet syndrome. Uses stereopure ASOs to increase protein expression, overlapping with Wave's oligonucleotide approach and genetic disease focus, though in different indications.

Emerging players

• Korro Bio: Emerging RNA editing company developing OPERA platform for ADAR-mediated RNA editing, with programs in alpha-1 antitrypsin deficiency (a direct overlap with WVE-006) and other genetic diseases. Earlier stage than Wave but pursues the same therapeutic modality.
• Beam Therapeutics: Clinical-stage base editing company using CRISPR-derived technology to make precise single-base corrections. While focused on DNA-level editing rather than RNA editing, Beam pursues similar genetic disease targets (e.g., alpha-1 antitrypsin deficiency, sickle cell disease) and represents an adjacent modality competing for the same patient populations.
• Solid Biosciences: Clinical-stage gene therapy company developing treatments for Duchenne muscular dystrophy, with SGT-003 in clinical trials. While using AAV gene therapy rather than oligonucleotides, Solid competes for the same DMD patient population as Wave's WVE-N531 and represents an alternative modality approach.

Broad incumbents

• Moderna: Large commercial-stage mRNA therapeutics company with extensive pipeline spanning rare diseases, oncology, and cardiometabolic indications. While focused on mRNA expression rather than oligonucleotide silencing/editing, Moderna pursues overlapping indications (including rare genetic diseases) and represents a broad incumbent with substantially greater capital and commercial resources.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/wavelifesci
• LinkedInlinkedin.com/company/wave-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries4 records

Funding overview

Funding rounds11 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wave Life Sciences